Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma.
To determine whether prostatic acid phosphatase (PAP) immunoreactivity in prostatic adenocarcinoma is a reliable prognostic factor, the PAP immunohistochemical distribution has been examined in 78 prostatic carcinoma cases. The intensity of PAP immunostaining was graded from 0 to 2, and the scores of the primary and the secondary staining patterns were added to assess the extent of the PAP expression in needle biopsy specimens. As a result, a higher cancer-specific survival rate was observed in patients showing a greater PAP immunostaining (P less than 0.01). Further, a multivariate analysis was made of possible prognostic factors (age, stage, Gleason score, serum PAP, PAP-immunostaining score, and the initial treatment) to estimate the extent of their impact on cancer-specific survival. Results have confirmed that the difference in PAP immunoreactivity is an excellent, independent prognostic factor for prostatic carcinoma.
Sakai
H
H
Department of Urology, Nagasaki University School of Medicine, Japan.
Shiraishi
K
K
Minami
Y
Y
Yushita
Y
Y
Kanetake
H
H
Saito
Y
Y
D000135:Acid Phosphatase / Q000032:analysis*; D000230:Adenocarcinoma / Q000201:enzymology* / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D004848:Epithelium / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D011467:Prostate / Q000201:enzymology*; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology
D000135:Acid Phosphatase